484 completed. 484 Phase 3, 33 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 484 | Completed 484 |
| Phase 2 | 33 | Completed 33 |
Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia JW0108 + C2407, JW0108 + C2407 placebo - Dyslipidemia | Phase 3 | Completed | JW Pharmaceutical | 145 | 2025-04-03 | 2025-09-03 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia SHR-1918, SHR-1918 placebo - Homozygous Familial Hypercholesterolemia | Phase 3 | Completed | Beijing Suncadia Pharmaceuticals Co., Ltd | 55 | 2025-02-13 | 2025-12-15 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R AG2304T, AG2304R - Hypercholesterolemia | Phase 3 | Completed | Ahn-Gook Pharmaceuticals Co.,Ltd | 158 | 2024-09-30 | 2026-06-18 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 301 | 2024-07-08 | 2026-03-27 |
| Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 1456 | 2024-05-21 | 2026-09-25 |
| Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism Vitamin D, Levothyroxin - Hypothyroidism Primary, Lipid Disorder | Phase 3 | Completed | King Edward Medical University | 62 | 2024-03-01 | 2025-03-11 |
| Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia | Phase 3 | Completed | NewAmsterdam Pharma | 407 | 2024-03-01 | 2025-10-08 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia SAL003 140 mg, Placebo - Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 720 | 2023-12-19 | 2025-11-28 |
| A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia SAL003 140 mg, Placebo - Hyperlipidemias | Phase 3 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 618 | 2023-10-23 | 2025-12-19 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2912 | 2023-08-10 | 2026-09-24 |
| A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 303 | 2023-08-08 | 2026-02-24 |
| Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. Inclisiran, Matching Placebo for Inclisiran - Primary Hypercholesterolemia or Mixed Dyslipidemia | Phase 3 | Completed | Novartis Pharmaceuticals | 207 | 2023-07-11 | 2026-01-13 |
| To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | 89bio, Inc. | 369 | 2023-06-15 | 2026-07-07 |
| A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily) - Hypercholesterolemia | Phase 3 | Completed | Kowa Company, Ltd. | 71 | 2023-05-01 | 2025-12-11 |
| Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. Inclisiran, Ezetimibe, Matching Placebo for Inclisiran - Hypercholesterolemia | Phase 3 | Completed | Novartis Pharmaceuticals | 350 | 2023-03-15 | 2025-10-16 |
| A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia (D) DWC202206, (D) DWC202207, (P) DWC202206 - Hypertension, Hyperlipidemias | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 214 | 2023-02-23 | 2026-04-30 |
| Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia Evinacumab - Homozygous Familial Hypercholesterolemia | Phase 3 | Completed | Daniel Gaudet | 10 | 2023-02-21 | 2025-03-25 |
Showing 20 of 484. Sign in to see all of them.
Hypercholesterolemia (229) · Hyperlipidemias (124) · Hypertension (50) · Hypertriglyceridemia (46) · Diabetes Mellitus, Type 2 (45) · Diabetes Mellitus (42) · Hyperlipoproteinemia Type II (38) · Coronary Disease (31) · Atherosclerosis (26) · Cardiovascular Diseases (26) · Glucose Metabolism Disorders (23) · Homozygous Familial Hypercholesterolemia (23) · Obesity (23) · Diabetes Mellitus, Lipoatrophic (10)
Nutritional and Metabolic Diseases (484) · Lipid Metabolism Disorders (478) · Metabolic Diseases (477) · Hyperlipidemias (261) · Vascular Diseases (104) · Cardiovascular Diseases (91) · Endocrine System Diseases (68) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (67) · Metabolism, Inborn Errors (65) · Lipid Metabolism, Inborn Errors (64) · Genetic Diseases, Inborn (63) · Hyperlipoproteinemias (58) · Glucose Metabolism Disorders (56) · Pathological Conditions, Signs and Symptoms (42)
Atorvastatin (87) · Ezetimibe (81) · Rosuvastatin Calcium (68) · Simvastatin (57) · evolocumab (30) · alirocumab (24) · Fenofibrate (23) · Pioglitazone (15) · Metformin (12) · pitavastatin (12) · Ezetimibe, Simvastatin Drug Combination (11) · Pravastatin (11) · Amlodipine (10) · alogliptin (10) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (9)
Organon and Co (57) · AstraZeneca (36) · Takeda (31) · Amgen (26) · Sanofi (20) · Merck Sharp & Dohme LLC (17) · Pfizer (14) · Abbott (11) · Kowa Research Europe (9) · Regeneron Pharmaceuticals (9) · Novartis Pharmaceuticals (8) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Solvay Pharmaceuticals (7) · Esperion Therapeutics, Inc. (6) · Kastle Therapeutics, LLC (6)
United States (188) · Canada (107) · Netherlands (75) · Germany (66) · South Africa (65) · Spain (59) · United Kingdom (59) · Czechia (58) · South Korea (57) · France (56) · Poland (56) · Italy (51) · Australia (46) · Hungary (46) · Denmark (42)
Russell Esterline (10) · Dragos Budinski, Med Dr. (5) · Ron Haberman, MD (5) · Dragos Budinski, MD (4) · Evan A Stein, MD PhD (3)
PMID 33078867, PMID 27777279, PMID 30183102, PMID 34298554, PMID 21518985, PMID 19793357, PMID 28304227, PMID 18783301, PMID 25614280, PMID 27578134, PMID 28964736, PMID 32609313, PMID 35916348, PMID 37994400, PMID 19744248, PMID 20136164, PMID 20573750, PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28391886, PMID 29685591, PMID 33990512, PMID 35277540, PMID 37658997, PMID 38063346, PMID 38757725, PMID 41604274, PMID 21174145, PMID 21401833, PMID 22087637, PMID 22263674, PMID 22500948, PMID 23325450, PMID 24014831, PMID 25269777, PMID 25431239, PMID 25893544, PMID 27116910, PMID 27206952, PMID 27418543, PMID 27596132, PMID 27939227, PMID 32187462, PMID 34989797, PMID 36520008, PMID 37282500, PMID 37565307, PMID 38018702
2005 (13), 2015 (10), 2017 (7), 2014 (5), 2023 (5), 2008 (3), 2016 (2), 2004 (1), 2018 (1), 2019 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1)